Medical use of cannabis for dry eye disease
The clinical value of cannabis in alleviating the symptoms of dry eye disease (DED) is limited at this time due to a lack of clinical evidence.
The Canadian Ophthalmological Society does not support the medical use of cannabis for the treatment of DED or its associated pain symptoms, due to its undesirable side-effects, including dry eye symptoms if smoked, and the absence of scientific evidence showing any beneficial effect at this time.
Other evidence-based, less harmful treatment modalities are available for DED and its associated symptoms.
Read the full position statement and recommendations from the Canadian Ophthalmological Society (COS).
So You Got a Complaint – Now What?!
Articles Patients’ complaints involving ophthalmologists in the province of Ontario,...
Immediate Sequential Bilateral Cataract Surgery (ISBCS) COVID-19 Considerations
Updated March, 2021 This document, which is subject to regular...
COVID-19 Vaccination Tool Kit for Health Care Providers
The current edition of the tool kit includes information on...
Can Ophthal Society's Twitter via Twitter Web Client
Redirecting to a Third-Party Website
You are now temporarily leaving the Practice Resource Centre. Clicking the button below will open a third-party website in a new browser tab. The website you are being redirected to is published by a third party and as such, its content is not under the control of the COS.
(If you do not wish to proceed, you can cancel this action by clicking the “X” in the corner of this message window)